Bharat Immunologicals and Biologicals Corporation Limited is an India-based biotechnology company. The Company is primarily engaged in the manufacture of oral polio vaccine, zinc tablet, and diarrhea management kit. It operates under various segment, namely oral polio vaccine, zinc tablets, BIB VIT, and BIBSANIT. It is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The Company is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). It is also diversified into plasma-derived medicines and Oral Cholera vaccines. The Company's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.
BHARAT IMMUNOLOGICALS & BIOLOG Financial Highlights
- Revenue: BHARAT IMMUNOLOGICALS & BIOLOG reported revenue of ₹45.67 crore in FY23 vs ₹79.49 crore in FY22. It showed a decrease of 42.55% on a yearly basis.
- Operating Profit: BHARAT IMMUNOLOGICALS & BIOLOG reported an operating loss of ₹22.27 crore in FY23 vs ₹9.69 crore in FY22. It showed a decrease of 129.82% on a year-on-year basis.
- Net Profit: BHARAT IMMUNOLOGICALS & BIOLOG reported a net loss of ₹16.64 crore in FY23 vs ₹8.75 crore in FY22. It showed a decrease of 90.17% on a yearly basis.
BHARAT IMMUNOLOGICALS & BIOLOG Quarterly Result Highlights
- BHARAT IMMUNOLOGICALS & BIOLOG reported revenue of ₹0.16 crore in Sep 2023, compared with ₹0.10 crore in Jun 2023, representing an increase of 60.00% on a quarter-on-quarter (QoQ) basis.
- BHARAT IMMUNOLOGICALS & BIOLOG reported an operating loss of ₹6.65 crore in Sep 2023, compared with ₹5.97 crore in Jun 2023, representing a decrease of 11.39% on a quarter-on-quarter (QoQ) basis.
- BHARAT IMMUNOLOGICALS & BIOLOG reported a loss of ₹4.92 crore in Sep 2023, compared with ₹4.59 crore in Jun 2023, reflecting a decrease of 7.19% on a QoQ basis.
- The earnings per share (EPS) of BHARAT IMMUNOLOGICALS & BIOLOG stood at ₹3.95 during Sep 2023.
